KIORA PHARMACEUTICALS, INC. Deferred Federal Income Tax Expense (Benefit)
KIORA PHARMACEUTICALS, INC. (KPRX) reported Deferred Federal Income Tax Expense (Benefit) of $4.14 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2025 was $4.14K.
- KIORA PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$75.38K.
- KIORA PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$280.95K, a 5771.26% decline from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2022 was $4.95K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.14K 10-K · filed 2026-03-25 | |
| 2024-12-31 | -$75.38K 10-K · filed 2026-03-25 | -$262.92K 10-K · filed 2025-03-25 |
| 2023-12-31 | -$280.95K 10-K · filed 2025-03-25 | |
| 2022-12-31 | $4.95K 10-K · filed 2024-03-25 | |
| 2021-12-31 | -$24.09K 10-K · filed 2023-03-23 | $190.94K 10-K · filed 2022-04-15 |
| 2020-12-31 | $529.00 10-K/A · filed 2022-07-07 | |
| 2019-12-31 | $4.18K 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$1.81K 10-K · filed 2020-03-04 | |
| 2017-12-31 | $1.16M 10-K · filed 2019-03-01 | -$1.16M 10-K · filed 2018-03-02 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |